Articles by Sanam Loghavi, MD
In a podcast, experts explore chemo-free ALL therapies, CAR T breakthroughs, and the future of T-cell–targeted treatments.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
Experts debate frontline CLL therapy—time-limited combos vs long-term BTKi—and the role of MRD in treatment decisions.
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
The panel considered whether it’s time for new response criteria in myelofibrosis such as anemia improvement.
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Live in Chicago, this podcast episode features a panel discussion on unanswered questions in AML.
“I’m grateful to shed a spotlight on hematopathology and what we contribute to these patients," Dr. Loghavi said.
Joseph Khoury, MD; Sanam Loghavi, MD; and Chadi Nabhan, MD, MBA, FACP, discuss the MDS classification systems.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.